The MINERVA platform is currently the most widely used platform for visualizing and providing access to disease maps. Disease maps are systems biological maps of molecular interactions relevant in a certain disease context, where they can be used to support drug discovery. For this purpose, we extended MINERVA's own drug and chemical search using the MINERVA plugin starter kit. We developed a plugin to provide a linkage between disease maps in MINERVA and application-specific databases of candidate therapeutics. The plugin has three main functionalities; one shows all the targets of all the compounds in the database, the second is a compound-based search to highlight targets of specific compounds, and the third can be used to find compounds that affect a certain target. As a use case, we applied the plugin to link a disease map and compound database we previously established in the context of cystic fibrosis and, herein, point out possible issues and difficulties. The plugin is publicly available on GitLab; the use-case application to cystic fibrosis, connecting disease maps and the compound database CandActCFTR, is available online.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8625161 | PMC |
http://dx.doi.org/10.3390/jpm11111072 | DOI Listing |
Alzheimers Dement
December 2024
Otsuka America Pharmaceutical Inc., Princeton, NJ, USA.
Background: Over the past 3 years, the Global Council on Alzheimer's Disease (GCAD) has conducted research on lived experience and care partner journeys. Specifically, this research has focused on the experiences of individuals from historically underrepresented populations, including LGBTQ+, Black, Hispanic/Latino, and Asian communities. The goal has been to identify how these journeys might diverge across communities, understand various nuances that exist across cultures, and recognize the impact these might have on seeking diagnosis, care, and support.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Weill Cornell Medicine, New York City, NY, USA.
Background: Early detection of Alzheimer's disease (AD) can improve prognosis, given new anti-amyloid therapies. Both positron emission tomography (PET) and magnetic resonance (MR) imaging biomarkers are currently used (1). 48F-Fluorodeoxyglucose-PET (FDG-PET) can detect neurodegeneration-related hypometabolism but is costly and not easily accessible (2).
View Article and Find Full Text PDFAlzheimers Dement
December 2024
MapHabit, Atlanta, GA, USA.
Background: The number of caregivers providing care for a family member or friend is on the rise. Dementia caregivers experience higher levels of stress and burden than caregivers of other chronic diseases due to the physical and emotional demands, and long duration of care provided. Thus, innovative tools are needed to aid in reducing caregiver stress and burden.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Global Brain Health Institute (GBHI), Trinity College Dublin (TCD), Dublin, Ireland.
Background: Socioeconomic disparities (SED) influence brain health and dementia. Latin America (LA) is characterized by high SED and a disproportionate prevalence of Alzheimer's disease (AD) and frontotemporal lobe degeneration (FTLD) compared to high-income populations like the United States (US). However, the impact of SED on brain reserve across neurocognitive pathways related to aging and dementia in LA remains unknown.
View Article and Find Full Text PDFRen Fail
December 2025
Department of Nephrology, Affiliated Hospital of Nantong University, Nantong, China.
Background: Chronic kidney disease (CKD) represents a significant global public health challenge. This study aims to identify biomarkers of renal fibrosis and elucidate the relationship between unilateral ureteral obstruction (UUO), immune infiltration, and cell death.
Methods: Gene expression matrices for UUO were retrieved from the gene expression omnibus (GSE36496, GSE79443, GSE217650, and GSE217654).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!